Effective interventions | The configuration most commonly associated with effectiveness (found in eight trials) involved one factor: ‘a focus on personal risk factors’ (pathway 1: [15–17, 19, 20, 23, 26, 27]). Other configurations each involved the presence of one factor, and the absence of other factors. One configuration involved ‘explaining the value of adherence’ with the absence of: |
(i) ‘Discuss circumstances that lead to forgetting to take treatment’ and ‘a focus on improving social support’ (pathway 2: [24, 25, 29]). | |
Or the absence of: | |
(i) ‘Discussion relating to not stopping the medication if there are no symptoms’ and ‘improving social support’ (pathway 3: [16, 18, 22, 29]). | |
The other configurations involved ‘provision of clear/appropriate information on how to take medication’, with the absence of: | |
(i) ‘Exploration of attitudes to therapy/disease’ and ‘discussion relating to not stopping taking medication if there are no symptoms’ (pathway 4:[17, 18, 22, 29]). | |
Or the absence of: | |
(ii) ‘Discussion relating to missing a drug’ and ‘discussion relating to not stopping taking medication if there are no symptoms’ (pathway 5: [24, 25, 27, 29]). | |
Or the absence of: | |
(iii) ‘Discussion relating to not stopping taking medication if there are no symptoms’ and ‘improving social support’ (pathway 6: [17, 18, 22, 29]). | |
Ineffective interventions | All four configurations (pathways) for the ineffective interventions included the absence of one factor: ‘a focus on personal risk factors’. Two of the configurations also involved the absence of either: |
(i) ‘Information on side effects’ and ‘pointing out the value of adherence’ (pathway 1: [31, 33–35]). | |
or | |
(ii) ‘Pointing out the value of adherence’ and ‘provision of clear or appropriate information’ (pathway 2: [30, 33–35]). | |
In the other two configurations the absence of ‘a focus on personal risk factors’ also involved the presence of either: | |
(i) ‘Discussion relating to missing a drug’ (pathway 3: [28, 30–32]). or | |
(ii) ‘Emphasis that experiencing no symptoms does not mean stopping medication’ (pathway 4: [21, 32]). |